Histiocytic Neoplasm, Neurofibromatosis Type 1-Associated Plexiform Neurofibromas, Other MAP-K Pathway Driven Diseases
Conditions
Keywords
RASopathies, NF1, Neurofibromatosis, Plexiform Neurofibromas, Langerhans
Brief summary
This program is being offered on a patient by patient basis and will require company, Institutional Review Board/Independent Ethics Committee, and applicable competent authority approval.
Interventions
Patients will receive oral mirdametinib.
Sponsors
SpringWorks Therapeutics, Inc., a healthcare company of Merck KGaA, Darmstadt, Germany
Eligibility
Sex/Gender
ALL
Age
2 Years to No maximum
Inclusion criteria
* Patient has a serious, debilitating or life-threatening medical condition that cannot be treated satisfactorily with an authorized medicinal product or other available standard treatment options, or all other treatment options have been exhausted. * Patient does not qualify to participate in an ongoing clinical trial.
Contacts
CONTACTUS Medical Information
Outcome results
None listed